[1]

Warner KD, Hajdin CE, Weeks KM. 2018. Principles for targeting RNA with drug-like small molecules. Nature Reviews Drug Discovery 17:547−558

doi: 10.1038/nrd.2018.93
[2]

The ENCODE Project Consortium. 2012. An integrated encyclopedia of DNA elements in the human genome. Nature 489:57−74

doi: 10.1038/nature11247
[3]

Saraswat A, Patki M, Fu Y, Barot S, Dukhande VV, et al. 2020. Nanoformulation of PROteolysis TArgeting Chimera targeting 'undruggable' c-Myc for the treatment of pancreatic cancer. Nanomedicine 15:1761−1777

doi: 10.2217/nnm-2020-0156
[4]

ClinicalTrials.gov. 2026. Search of RNA-targeting therapeutics clinical trials. U.S. National Library of Medicine. https://clinicaltrials.gov/ (accessed on 17 May 2026)
[5]

Khorkova O, Stahl J, Joji A, Volmar CH, Wahlestedt C. 2023. Amplifying gene expression with RNA-targeted therapeutics. Nature Reviews Drug Discovery 22:539−561

doi: 10.1038/s41573-023-00704-7
[6]

Childs-Disney JL, Tsitovich PB, Disney MD. 2011. Using modularly assembled ligands to bind RNA internal loops separated by different distances. ChemBioChem 12:2143−2146

doi: 10.1002/cbic.201100298
[7]

Menduti G, Rasà DM, Stanga S, Boido M. 2020. Drug screening and drug repositioning as promising therapeutic approaches for spinal muscular atrophy treatment. Frontiers in Pharmacology 11:592234

doi: 10.3389/fphar.2020.592234
[8]

Ratni H, Ebeling M, Baird J, Bendels S, Bylund J, et al. 2018. Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). Journal of Medicinal Chemistry 61:6501−6517

doi: 10.1021/acs.jmedchem.8b00741
[9]

Dhillon S. 2020. Risdiplam: first approval. Dråugs 80:1853−1858

doi: 10.1007/s40265-020-01410-z
[10]

Xiao L, Kang S, Djordjevic D, Gonorazky H, Chiang J, et al. 2023. Understanding caregiver experiences with disease-modifying therapies for spinal muscular atrophy: a qualitative study. Archives of Disease in Childhood 108:929−934

doi: 10.1136/archdischild-2023-325762
[11]

Childs-Disney JL, Yang X, Gibaut QMR, Tong Y, Batey RT, et al. 2022. Targeting RNA structures with small molecules. Nature Reviews Drug Discovery 21:736−762

doi: 10.1038/s41573-022-00521-4
[12]

Tong Y, Lee Y, Liu X, Childs-Disney JL, Suresh BM, et al. 2023. Programming inactive RNA-binding small molecules into bioactive degraders. Nature 618:169−179

doi: 10.1038/s41586-023-06091-8
[13]

Tong Y, Gibaut QMR, Rouse W, Childs-Disney JL, Suresh BM, et al. 2022. Transcriptome-wide mapping of small-molecule RNA-binding sites in cells informs an isoform-specific degrader of QSOX1 mRNA. Journal of the American Chemical Society 144:11620−11625

doi: 10.1021/jacs.2c01929
[14]

Xiong W, Liu X, Qi Q, Li Y, Huang S, et al. 2025. Bioorthogonal RNase L recruitment enables targeted inducible degradation of SARS-CoV-2 RNA. Angewandte Chemie International Edition 64:e202515064

doi: 10.1002/anie.202515064
[15]

Bian T, Gao S, Sun X, Zhou S, Pei Y, et al. 2025. Single-molecule detection on intrastrand interactions among G4 clusters. Analytical Chemistry 97:11617−11626

doi: 10.1021/acs.analchem.5c00884
[16]

Zhao L, Zhao J, Zhong K, Tong A, Jia D. 2022. Targeted protein degradation: mechanisms, strategies and application. Signal Transduction and Targeted Therapy 7:113

doi: 10.1038/s41392-022-00966-4
[17]

Fang Y, Wang J, Zhao M, Zheng Q, Ren C, et al. 2022. Progress and challenges in targeted protein degradation for neurodegenerative disease therapy. Journal of Medicinal Chemistry 65:11454−11477

doi: 10.1021/acs.jmedchem.2c00844
[18]

Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, et al. 2001. Protacs: chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation. Proceedings of the National Academy of Sciences of the United States of America 98:8554−8559

doi: 10.1073/pnas.141230798
[19]

Domostegui A, Nieto-Barrado L, Perez-Lopez C, Mayor-Ruiz C. 2022. Chasing molecular glue degraders: screening approaches. Chemical Society Reviews 51:5498−5517

doi: 10.1039/D2CS00197G
[20]

Wu S, Xiao H, Sun Q. 2021. New approaches for small molecule-induced protein degradation. Future Medicinal Chemistry 13:439−441

doi: 10.4155/fmc-2020-0343
[21]

Henning NJ, Boike L, Spradlin JN, Ward CC, Liu G, et al. 2022. Deubiquitinase-targeting chimeras for targeted protein stabilization. Nature Chemical Biology 18:412−421

doi: 10.1038/s41589-022-00971-2
[22]

Chen P-H, Hu Z, An E, Okeke I, Zheng S, et al. 2021. Modulation of phosphoprotein activity by phosphorylation targeting chimeras (PhosTACs). ACS Chemical Biology 16:2808−2815

doi: 10.1021/acschembio.1c00693
[23]

Costales MG, Matsumoto Y, Velagapudi SP, Disney MD. 2018. Small molecule targeted recruitment of a nuclease to RNA. Journal of the American Chemical Society 140:6741−6744

doi: 10.1021/jacs.8b01233
[24]

Costales MG, Suresh B, Vishnu K, Disney MD. 2019. Targeted degradation of a hypoxia-associated non-coding RNA enhances the selectivity of a small molecule interacting with RNA. Cell Chemical Biology 26:1180−1186.e5

doi: 10.1016/j.chembiol.2019.04.008
[25]

Costales MG, Aikawa H, Li Y, Childs-Disney JL, Abegg D, et al. 2020. Small-molecule targeted recruitment of a nuclease to cleave an oncogenic RNA in a mouse model of metastatic cancer. Proceedings of the National Academy of Sciences of the United States of America 117:2406−2411

doi: 10.1073/pnas.1914286117
[26]

Guan L, Disney MD. 2013. Small-molecule-mediated cleavage of RNA in living cells. Angewandte Chemie International Edition 52:1462−1465

doi: 10.1002/ange.201206888
[27]

Haj-Yahia S, Nandi A, Benhamou RI. 2023. Targeted degradation of structured RNAs via ribonuclease-targeting chimeras (RiboTacs). Expert Opinion on Drug Discovery 18:929−942

doi: 10.1080/17460441.2023.2224960
[28]

Kubota K, Nakahara K, Ohtsuka T, Yoshida S, Kawaguchi J, et al. 2004. Identification of 2'-phosphodiesterase, which plays a role in the 2-5A system regulated by interferon. Journal of Biological Chemistry 279:37832−37841

doi: 10.1074/jbc.M400089200
[29]

Kargbo RB. 2021. RIBOTACs: small molecules selectively destroy cancer-associated RNA. ACS Medicinal Chemistry Letters 12:1872−1873

doi: 10.1021/acsmedchemlett.1c00576
[30]

Liang X-H, Sun H, Shen W, Crooke ST. 2015. Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages. Nucleic Acids Research 43:2927−2945

doi: 10.1093/nar/gkv143
[31]

Wang W, He S, Dong G, Sheng C. 2022. Nucleic-acid-based targeted degradation in drug discovery. Journal of Medicinal Chemistry 65:10217−10232

doi: 10.1021/acs.jmedchem.2c00875
[32]

Meyer SM, Williams CC, Akahori Y, Tanaka T, Aikawa H, et al. 2020. Small molecule recognition of disease-relevant RNA structures. Chemical Society Reviews 49:7167−7199

doi: 10.1039/D0CS00560F
[33]

Gao X, Wu Z. 2025. IRES-mediated translation: expanding the toolkits of RNA therapy. International Journal of Molecular Sciences 26:10542

doi: 10.3390/ijms262110542
[34]

Khaskia E, Dahatonde D, Benhamou RI. 2025. RNA G-quadruplex RIBOTAC-mediated targeted degradation of lncRNA TERRA. Advanced Science 12:e12715

doi: 10.1002/advs.202512715
[35]

Cullen BR. 2004. Transcription and processing of human microRNA precursors. Molecular Cell 16:861−865

doi: 10.1016/j.molcel.2004.12.002
[36]

Ha M, Kim VN. 2014. Regulation of microRNA biogenesis. Nature Reviews Molecular Cell Biology 15:509−524

doi: 10.1038/nrm3838
[37]

Bohnsack MT, Czaplinski K, Gorlich D. 2004. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 10:185−191

doi: 10.1261/rna.5167604
[38]

Starega-Roslan J, Galka-Marciniak P, Krzyzosiak WJ. 2015. Nucleotide sequence of miRNA precursor contributes to cleavage site selection by Dicer. Nucleic Acids Research 43:10939−10951

doi: 10.1093/nar/gkv968
[39]

Childs-Disney JL, Disney MD. 2015. Small molecule targeting of a microRNA associated with hepatocellular carcinoma. ACS Chemical Biology 11:375−380

doi: 10.1021/acschembio.5b00615.s001
[40]

Costales MG, Haga CL, Velagapudi SP, Childs-Disney JL, Phinney DG, et al. 2017. Small molecule inhibition of microRNA-210 reprograms an oncogenic hypoxic circuit. Journal of the American Chemical Society 139:3446−3455

doi: 10.1021/jacs.6b11273
[41]

Gilam A, Conde J, Weissglas-Volkov D, Oliva N, Friedman E, et al. 2016. Local microRNA delivery targets Palladin and prevents metastatic breast cancer. Nature Communications 7:12868

doi: 10.1038/ncomms12868
[42]

Velagapudi SP, Gallo SM, Disney MD. 2014. Sequence-based design of bioactive small molecules that target precursor microRNAs. Nature Chemical Biology 10:291−297

doi: 10.1038/nchembio.1452
[43]

Velagapudi SP, Cameron MD, Haga CL, Rosenberg LH, Lafitte M, et al. 2016. Design of a small molecule against an oncogenic noncoding RNA. Proceedings of the National Academy of Sciences of the United States of America 113:5898−5903

doi: 10.1073/pnas.1523975113
[44]

Li Y, Disney MD. 2018. Precise small molecule degradation of a noncoding RNA identifies cellular binding sites and modulates an oncogenic phenotype. ACS Chemical Biology 13:3065−3071

doi: 10.1021/acschembio.8b00827
[45]

Kwok CK, Merrick CJ. 2017. G-quadruplexes: Prediction, characterization, and biological application. Trends in Biotechnology 35:997−1013

doi: 10.1016/j.tibtech.2017.06.012
[46]

Rosenberg M, Paterson BM. 1979. Efficient cap-dependent translation of polycistronic prokaryotic mRNAs is restricted to the first gene in the operon. Nature 279:696−701

doi: 10.1038/279696a0
[47]

Davila-Calderon J, Patwardhan NN, Chiu LY, Sugarman A, Cai Z, et al. 2020. IRES-targeting small molecule inhibits enterovirus 71 replication via allosteric stabilization of a ternary complex. Nature Communications 11:4775

doi: 10.1038/s41467-020-18594-3
[48]

Péladeau C, Jasmin BJ. 2021. Targeting IRES-dependent translation as a novel approach for treating Duchenne muscular dystrophy. RNA Biology 18:1238−1251

doi: 10.1080/15476286.2020.1847894
[49]

Kozak M, Shatkin AJ. 1978. Migration of 40 S ribosomal subunits on messenger RNA in the presence of edeine. Journal of Biological Chemistry 253:6568−6577

doi: 10.1016/S0021-9258(19)46969-X
[50]

Nanbru C, Lafon I, Audigier S, Gensac MC, Vagner S, et al. 1997. Alternative translation of the proto-oncogene c-myc by an internal ribosome entry site. Journal of Biological Chemistry 272:32061−32066

doi: 10.1074/jbc.272.51.32061
[51]

Lee ASY, Kranzusch PJ, Cate JHD. 2015. eIF3 targets cell-proliferation messenger RNAs for translational activation or repression. Nature 522:111−114

doi: 10.1038/nature14267
[52]

Lee AS, Kranzusch PJ, Doudna JA, Cate JHD. 2016. eIF3d is an mRNA cap-binding protein that is required for specialized translation initiation. Nature 536:96−99

doi: 10.1038/nature18954
[53]

Ding Y, Fei Y, Lu B. 2020. Emerging new concepts of degrader technologies. Trends in Pharmacological Sciences 41:464−474

doi: 10.1016/j.tips.2020.04.005
[54]

Lee Y, Rio DC. 2015. Mechanisms and regulation of alternative pre-mRNA splicing. Annual Review of Biochemistry 84:291−323

doi: 10.1146/annurev-biochem-060614-034316
[55]

Ule J, Blencowe BJ. 2019. Alternative splicing regulatory networks: functions, mechanisms, and evolution. Molecular Cell 76:329−345

doi: 10.1016/j.molcel.2019.09.017
[56]

Sazani P, Kole R. 2003. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. Journal of Clinical Investigation 112:481−486

doi: 10.1172/JCI19547
[57]

Zheng S, Chen Y, Donahue CP, Wolfe MS, Varani G. 2009. Structural basis for stabilization of the tau pre-mRNA splicing regulatory element by novantrone (mitoxantrone). Chemistry & Biology 16:557−566

doi: 10.1016/j.chembiol.2009.03.009
[58]

Messina S, Sframeli M. 2020. New treatments in spinal muscular atrophy: positive results and new challenges. Journal of Clinical Medicine 9:2222

doi: 10.3390/jcm9072222
[59]

Wang Z-F, Ursu A, Childs-Disney JL, Guertler R, Yang WY, et al. 2019. The hairpin form of r(G4C2) exp in c9ALS/FTD is repeat-associated non-ATG translated and a target for bioactive small molecules. Cell Chemical Biology 26:179−190.e12

doi: 10.1016/j.chembiol.2018.10.018
[60]

Bush JA, Aikawa H, Fuerst R, Li Y, Ursu A, et al. 2021. Ribonuclease recruitment using a small molecule reduced c9ALS/FTD r(G4C2) repeat expansion in vitro and in vivo ALS models. Science Translational Medicine 13:eabd5991

doi: 10.1126/scitranslmed.abd5991
[61]

Kumar V, Hasan GM, Hassan MI. 2017. Unraveling the role of RNA mediated toxicity of C9orf72 repeats in C9-FTD/ALS. Frontiers in Neuroscience 11:711

doi: 10.3389/fnins.2017.00711
[62]

Jahromi AH, Fu Y, Miller KA, Nguyen L, Luu LM, et al. 2013. Developing bivalent ligands to target CUG triplet repeats, the causative agent of myotonic dystrophy type 1. Journal of Medicinal Chemistry 56:9471−9481

doi: 10.1021/jm400794z
[63]

Jog SP, Paul S, Dansithong W, Tring S, Comai L, et al. 2012. RNA splicing is responsive to MBNL1 dose. PLoS One 7:e48825

doi: 10.1371/journal.pone.0048825
[64]

Angelbello AJ, DeFeo ME, Glinkerman CM, Boger DL, Disney MD. 2020. Precise targeted cleavage of a r(CUG) repeat expansion in cells by using a small-molecule-deglycobleomycin conjugate. ACS Chemical Biology 15:849−855

doi: 10.1021/acschembio.0c00036
[65]

La Spada AR, Taylor JP. 2010. Repeat expansion disease: progress and puzzles in disease pathogenesis. Nature Reviews Genetics 11:247−258

doi: 10.1038/nrg2748
[66]

Gendron TF, Belzil VV, Zhang YJ, Petrucelli L. 2014. Mechanisms of toxicity in C9FTLD/ALS. Acta Neuropathologica 127:359−376

doi: 10.1007/s00401-013-1237-z
[67]

Angelbello AJ, Disney MD. 2018. Bleomycin can cleave an oncogenic noncoding RNA. ChemBioChem 19:43−47

doi: 10.1002/cbic.201700581
[68]

Benhamou RI, Abe M, Choudhary S, Meyer SM, Angelbello AJ, et al. 2020. Optimization of the linker domain in a dimeric compound that degrades an r(CUG) repeat expansion in cells. Journal of Medicinal Chemistry 63:7827−7839

doi: 10.1021/acs.jmedchem.0c00558
[69]

Disney MD, Angelbello AJ. 2016. Rational design of small molecules targeting oncogenic noncoding RNAs from sequence. Accounts of Chemical Research 49:2698−2704

doi: 10.1021/acs.accounts.6b00326
[70]

Garner AL, Lorenz DA, Sandoval J, Gallagher EE, Kerk SA, et al. 2019. Tetracyclines as inhibitors of pre-microRNA maturation: a disconnection between RNA binding and inhibition. ACS Medicinal Chemistry Letters 10:816−821

doi: 10.1021/acsmedchemlett.9b00091
[71]

Pomplun S, Gates ZP, Zhang G, Quartararo AJ, Pentelute BL. 2020. Discovery of nucleic acid binding molecules from combinatorial biohybrid nucleobase peptide libraries. Journal of the American Chemical Society 142:19642−19651

doi: 10.1021/jacs.0c08964
[72]

Vo DD, Tran TPA, Staedel C, Benhida R, Darfeuille F, et al. 2016. Oncogenic MicroRNAs biogenesis as a drug target: structure–activity relationship studies on new aminoglycoside conjugates. Chemistry 22:5350−5362

doi: 10.1002/chem.201505094
[73]

Disney MD, Childs JL, Turner DH. 2004. Hoechst 33258 selectively inhibits group I intron self-splicing by affecting RNA folding. ChemBioChem 5:1647−1652

doi: 10.1002/cbic.200400159
[74]

Velagapudi SP, Seedhouse SJ, French J, Disney MD. 2011. Defining the RNA internal loops preferred by benzimidazole derivatives via 2D combinatorial screening and computational analysis. Journal of the American Chemical Society 133:10111−10118

doi: 10.1021/ja200212b
[75]

Tran T, Disney MD. 2012. Identifying the preferred RNA motifs and chemotypes that interact by probing millions of combinations. Nature Communications 3:1125

doi: 10.1038/ncomms2119
[76]

Parkesh R, Childs-Disney JL, Nakamori M, Kumar A, Wang E, et al. 2012. Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif-ligand database and chemical similarity searching. Journal of the American Chemical Society 134:4731−4742

doi: 10.1021/ja210088v
[77]

Guan L, Disney MD. 2013. Covalent small-molecule-RNA complex formation enables cellular profiling of small-molecule-RNA interactions. Angewandte Chemie International Edition 52:10010−10013

doi: 10.1002/anie.201301639
[78]

Disney MD, Liu B, Yang WY, Sellier C, Tran T, et al. 2012. A small molecule that targets r(CGG)(exp) and improves defects in fragile X-associated tremor ataxia syndrome. ACS Chemical Biology 7:1711−1718

doi: 10.1021/cb300135h
[79]

Su Z, Zhang Y, Gendron TF, Bauer PO, Chew J, et al. 2014. Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. Neuron 83:1043−1050

doi: 10.1016/j.neuron.2014.07.041
[80]

Rzuczek SG, Southern MR, Disney MD. 2015. Studying a drug-like, RNA-focused small molecule library identifies compounds that inhibit RNA toxicity in myotonic dystrophy. ACS Chemical Biology 10:2706−2715

doi: 10.1021/acschembio.5b00430
[81]

Costales MG, Hoch DG, Abegg D, Childs-Disney JL, Velagapudi SP, et al. 2019. A designed small molecule inhibitor of a non-coding RNA sensitizes HER2 negative cancers to Herceptin. Journal of the American Chemical Society 141:2960−2974

doi: 10.1021/jacs.8b10558
[82]

Suresh BM, Li W, Zhang P, Wang KW, Yildirim I, et al. 2020. A general fragment-based approach to identify and optimize bioactive ligands targeting RNA. Proceedings of the National Academy of Sciences of the United States of America 117:33197−33203

doi: 10.1073/pnas.2012217117
[83]

Haniff HS, Knerr L, Liu X, Crynen G, Boström J, et al. 2020. Design of a small molecule that stimulates vascular endothelial growth factor A enabled by screening RNA fold-small molecule interactions. Nature Chemistry 12:952−961

doi: 10.1038/s41557-020-0514-4
[84]

Wagner-Griffin S, Abe M, Benhamou RI, Angelbello AJ, Vishnu K, et al. 2021. A druglike small molecule that targets r(CCUG) repeats in myotonic dystrophy type 2 facilitates degradation by RNA quality control pathways. Journal of Medicinal Chemistry 64:8474−8485

doi: 10.1021/acs.jmedchem.1c00414
[85]

Angelbello AJ, Benhamou RI, Rzuczek SG, Choudhary S, Tang Z, et al. 2021. A small molecule that binds an RNA repeat expansion stimulates its decay via the exosome complex. Cell Chemical Biology 28: 34−45.e6

doi: 10.1016/j.chembiol.2020.10.007
[86]

Tong Y, Zhang P, Yang X, Liu X, Zhang J, et al. 2024. Decreasing the intrinsically disordered protein α-synuclein levels by targeting its structured mRNA with a ribonuclease-targeting chimera. Proceedings of the National Academy of Sciences of the United States of America 121:e2306682120

doi: 10.1073/pnas.2306682120
[87]

Meyer SM, Tanaka T, Zanon PRA, Baisden JT, Abegg D, et al. 2022. DNA-encoded library screening to inform design of a ribonuclease targeting chimera (RiboTAC). Journal of the American Chemical Society 144:21096−21102

doi: 10.1021/jacs.2c07217
[88]

Liu X, Haniff HS, Childs-Disney JL, Shuster A, Aikawa H, et al. 2020. Targeted degradation of the oncogenic MicroRNA 17-92 cluster by structure-targeting ligands. Journal of the American Chemical Society 142:6970−6982

doi: 10.1021/jacs.9b13159
[89]

Disney MD, Childs‐Disney JL. 2007. Using selection to identify and chemical microarray to study the RNA internal loops recognized by 6'-N-acylated Kanamycin A. ChemBioChem 8:649−656

doi: 10.1002/cbic.200600569
[90]

Disney MD, Labuda LP, Paul DJ, Poplawski SG, Pushechnikov A, et al. 2008. Two-dimensional combinatorial screening identifies specific aminoglycoside–RNA internal loop partners. Journal of the American Chemical Society 130:11185−11194

doi: 10.1021/ja803234t
[91]

Lee MM, Pushechnikov A, Disney MD. 2009. Rational and modular design of potent ligands targeting the RNA that causes myotonic dystrophy 2. ACS Chemical Biology 4:345−355

doi: 10.1021/cb900025w
[92]

Kumar A, Parkesh R, Sznajder LJ, Childs-Disney JL, Sobczak K, et al. 2012. Chemical correction of pre-mRNA splicing defects associated with sequestration of muscleblind-like 1 protein by expanded r(CAG)-containing transcripts. ACS Chemical Biology 7:496−505

doi: 10.1021/cb200413a
[93]

Yang WY, Gao R, Southern M, Sarkar PS, Disney MD. 2016. Design of a bioactive small molecule that targets r(AUUCU) repeats in spinocerebellar ataxia 10. Nature Communications 7:11647

doi: 10.1038/ncomms11647
[94]

Childs-Disney JL, Stepniak-Konieczna E, Tran T, Yildirim I, Park H, et al. 2013. Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Nature Communications 4:2044

doi: 10.1038/ncomms3044
[95]

Haga CL, Velagapudi SP, Strivelli JR, Yang W-Y, Disney MD, et al. 2015. Small molecule inhibition of miR-544 biogenesis disrupts adaptive responses to hypoxia by modulating ATM-mTOR signaling. ACS Chemical Biology 10:2267−2276

doi: 10.1021/acschembio.5b00265
[96]

Hoskins JW, Ofori LO, Chen CZ, Kumar A, Sobczak K, et al. 2014. Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects. Nucleic Acids Research 42:6591−6602

doi: 10.1093/nar/gku275
[97]

Velagapudi SP, Costales MG, Vummidi BR, Nakai Y, Angelbello AJ, et al. 2018. Approved anti-cancer drugs target oncogenic non-coding RNAs. Cell Chemical Biology 25:1086−1094.e7

doi: 10.1016/j.chembiol.2018.05.015
[98]

Haniff HS, Tong Y, Liu X, Chen JL, Suresh BM, et al. 2020. Targeting the SARS-CoV-2 RNA genome with small molecule binders and ribonuclease targeting chimera (RIBOTAC) degraders. ACS Central Science 6:1713−1721

doi: 10.1021/acscentsci.0c00984
[99]

Ursu A, Baisden JT, Bush JA, Taghavi A, Choudhary S, et al. 2021. A small molecule exploits hidden structural features within the RNA repeat expansion that causes c9ALS/FTD and rescues pathological hallmarks. ACS Chemical Neuroscience 12:4076−4089

doi: 10.1021/acschemneuro.1c00470
[100]

Suresh BM, Akahori Y, Taghavi A, Crynen G, Gibaut QMR, et al. 2022. Low-molecular weight small molecules can potently bind RNA and affect oncogenic pathways in cells. Journal of the American Chemical Society 144:20815−20824

doi: 10.1021/jacs.2c08770
[101]

Pernodet N, Hermetet F, Adami P, Vejux A, Descotes F, et al. 2012. High expression of QSOX1 reduces tumorogenesis, and is associated with a better outcome for breast cancer patients. Breast Cancer Research 14:R136

doi: 10.1186/bcr3341
[102]

Suresh BM, Tong Y, Abegg D, Adibekian A, Childs-Disney JL, et al. 2023. Altering the cleaving effector in chimeric molecules that target RNA enhances cellular selectivity. ACS Chemical Biology 18:2385−2393

doi: 10.1021/acschembio.3c00363
[103]

Wirth B. 2000. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Human Mutation 15:228−237

doi: 10.1002/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9
[104]

Palacino J, Swalley SE, Song C, Cheung AK, Shu L, et al. 2015. SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. Nature Chemical Biology 11:511−517

doi: 10.1038/nchembio.1837
[105]

Mercure S, Montplaisir S, Lemay G. 1993. Correlation between the presence of a self-splicing intron in the 25S rDNA of C.albicans and strains susceptibility to 5-fluorocytosine. Nucleic Acids Research 21:6020−6027

doi: 10.1093/nar/21.25.6020
[106]

Bubenik JL, Scotti MM, Swanson MS. 2024. Therapeutic targeting of RNA for neurological and neuromuscular disease. Genes & Development 38:698−717

doi: 10.1101/gad.351612.124
[107]

Carter AP, Clemons WM, Brodersen DE, Morgan-Warren RJ, Wimberly BT, et al. 2000. Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature 407:340−348

doi: 10.1038/35030019
[108]

Moazed D, Noller HF. 1987. Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature 327:389−394

doi: 10.1038/327389a0
[109]

Recht MI, Fourmy D, Blanchard SC, Dahlquist KD, Puglisi JD. 1996. RNA sequence determinants for aminoglycoside binding to an a-site rRNA model oligonucleotide. Journal of Molecular Biology 262:421−436

doi: 10.1006/jmbi.1996.0526
[110]

Lee MM, Childs-Disney JL, Pushechnikov A, French JM, Sobczak K, et al. 2009. Controlling the specificity of modularly assembled small molecules for RNA via ligand module spacing: targeting the RNAs that cause myotonic muscular dystrophy. Journal of the American Chemical Society 131:17464−17472

doi: 10.1021/ja906877y
[111]

Silva JG, Carvalho I. 2007. New insights into aminoglycoside antibiotics and derivatives. Current Medicinal Chemistry 14:1101−1119

doi: 10.2174/092986707780362817
[112]

Labuda LP, Pushechnikov A, Disney MD. 2009. Small molecule microarrays of RNA-focused peptoids help identify inhibitors of a pathogenic group I intron. ACS Chemical Biology 4:299−307

doi: 10.1021/cb800313m
[113]

Li H, Dong J, Cai M, Xu Z, Cheng X-D, et al. 2021. Protein degradation technology: a strategic paradigm shift in drug discovery. Journal of Hematology & Oncology 14:138

doi: 10.1186/s13045-021-01146-7
[114]

Mikutis S, Rebelo M, Yankova E, Gu M, Tang C, et al. 2023. Proximity-induced nucleic acid degrader (PINAD) approach to targeted RNA degradation using small molecules. ACS Central Science 9:892−904

doi: 10.1021/acscentsci.3c00015
[115]

Bonet-Aleta J, Maehara T, Craig BA, Bernardes GJL. 2024. Small molecule RNA degraders. Angewandte Chemie International Edition 63:e202412925

doi: 10.1002/anie.202412925
[116]

Ursu A, Childs-Disney JL, Andrews RJ, O’Leary CA, Meyer SM, et al. 2020. Design of small molecules targeting RNA structure from sequence. Chemical Society Reviews 49:7252−7270

doi: 10.1039/D0CS00455C
[117]

Disney MD. 2019. Targeting RNA with small molecules to capture opportunities at the intersection of chemistry, biology, and medicine. Journal of the American Chemical Society 141:6776−6790

doi: 10.1021/jacs.8b13419
[118]

Childs-Disney JL, Tran T, Vummidi BR, Velagapudi SP, Haniff HS, et al. 2018. A massively parallel selection of small molecule-RNA motif binding partners informs design of an antiviral from sequence. Chem 4:2384−2404

doi: 10.1016/j.chempr.2018.08.003
[119]

Garner AL, Lorenz DA, Gallagher EE. 2019. A click chemistry assay to identify natural product ligands for pre-microRNAs. Methods in Enzymology 623:85−99

doi: 10.1016/bs.mie.2019.04.020
[120]

Borgelt L, Haacke N, Lampe P, Qiu X, Gasper R, et al. 2022. Small-molecule screening of ribonuclease L binders for RNA degradation. Biomed Pharmacother 154:113589

doi: 10.1016/j.biopha.2022.113589
[121]

Malathi K, Paranjape JM, Ganapathi R, Silverman RH. 2004. HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2', 5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand. Cancer Research 64:9144−9151

doi: 10.1158/0008-5472.CAN-04-2226
[122]

Loureiro RJ, Maiti S, Mondal K, Mukherjee S, Bujnicki JM. 2025. Modeling flexible RNA 3D structures and RNA-protein complexes. Current Opinion in Structural Biology 94:103137

doi: 10.1016/j.sbi.2025.103137
[123]

Dilliard SA, Cheng Q, Siegwart DJ. 2021. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proceedings of the National Academy of Sciences of the United States of America 118:e2109256118

doi: 10.1073/pnas.2109256118
[124]

Rzuczek SG, Gao Y, Tang ZZ, Thornton CA, Kodadek T, et al. 2013. Features of modularly assembled compounds that impart bioactivity against an RNA target. ACS Chemical Biology 8:2312−2321

doi: 10.1021/cb400265y
[125]

Sadler AJ, Williams BRG. 2008. Interferon-inducible antiviral effectors. Nature Reviews Immunology 8:559−568

doi: 10.1038/nri2314
[126]

Rebouillat D, Hovanessian AG. 1999. The human 2', 5'-oligoadenylate synthetase family: Interferon-induced proteins with unique enzymatic properties. Journal of Interferon & Cytokine Research 19:295−308

doi: 10.1089/107999099313992
[127]

Takenaka Y, Yamada A, Tomioka Y, Akiyama Y, Ivanov P. 2025. RNase L produces tRNA-derived RNAs that contribute to translation inhibition. RNA 31:961−972

doi: 10.1261/rna.080419.125
[128]

Tang Z, Hegde S, Hao S, Selvaraju M, Qiu J, et al. 2025. Chemical-guided SHAPE sequencing (cgSHAPE-seq) informs the binding site of RNA-degrading chimeras targeting SARS-CoV-2 5' untranslated region. Nature Communications 16:483

doi: 10.1101/2023.04.03.535453
[129]

Thakur CS, Jha BK, Dong B, Das Gupta J, Silverman KM, et al. 2007. Small-molecule activators of RNase L with broad-spectrum antiviral activity. Proceedings of the National Academy of Sciences of the United State of America 104:9585−9590

doi: 10.1073/pnas.0700590104
[130]

Thakur CS, Xu Z, Wang Z, Novince Z, Silverman RH. 2005. A convenient and sensitive fluorescence resonance energy transfer assay for RNase L and 2',5' oligoadenylates. Methods in Molecular Medicine 116:103−113

doi: 10.1385/1-59259-939-7:103
[131]

Zuker M. 2003. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Research 31:3406−3415

doi: 10.1093/nar/gkg595
[132]

Rzuczek SG, Colgan LA, Nakai Y, Cameron MD, Furling D, et al. 2017. Precise small-molecule recognition of a toxic CUG RNA repeat expansion. Nature Chemical Biology 13:188−193

doi: 10.1038/nchembio.2251
[133]

Xu W, Biswas J, Singer RH, Rosbash M. 2022. Targeted RNA editing: Novel tools to study post-transcriptional regulation. Molecular Cell 82:389−403

doi: 10.1016/j.molcel.2021.10.010
[134]

Meyer SM, Kovachka S, Wang T, Cameron MD, Childs-Disney JL, et al. 2025. Linker optimization enhances the potency of ribonuclease-targeting chimeras in cancer models. Journal of Medicinal Chemistry 68:12881−12903

doi: 10.1021/acs.jmedchem.5c00749
[135]

Jiao Z, Song C, Sha X, Chen Y, Xing Y, et al. 2025. Targeted RNA degradation via LipoSM-RiboTAC nanoparticles: a versatile platform for cancer therapy. Journal of the American Chemical Society 147:42209−42220
[136]

Fang Y, Wu Q, Wang F, Liu Y, Zhang H, et al. 2025. Aptamer-RIBOTAC strategy enabling tumor-dpecific targeted degradation of microRNA for precise cancer therapy. Small Methods 9:e2400349

doi: 10.1002/smtd.202400349
[137]

Ellenbroek BD, Kahler JP, Evers SR, Pomplun SJ. 2024. Synthetic peptides: promising modalities for the targeting of disease-related nucleic acids. Angewandte Chemie, International Edition 63:e202401704

doi: 10.1002/anie.202401704
[138]

Morishita EC, Nakamura S. 2024. Recent applications of artificial intelligence in RNA-targeted small molecule drug discovery. Expert Opinion on Drug Discovery 19:415−431

doi: 10.1080/17460441.2024.2313455
[139]

Mullowney MW, Duncan KR, Elsayed SS, Garg N, van der Hooft JJJ, et al. 2023. Artificial intelligence for natural product drug discovery. Nature Reviews Drug Discovery 22:895−916

doi: 10.1038/s41573-023-00774-7
[140]

Sato K, Hamada M. 2023. Recent trends in RNA informatics: a review of machine learning and deep learning for RNA secondary structure prediction and RNA drug discovery. Briefings in Bioinformatics 24:bbad186

doi: 10.1093/bib/bbad186
[141]

Disney MD, Winkelsas AM, Velagapudi SP, Southern M, Fallahi M. 2016. Inforna 2.0: a platform for the sequence-based design of small molecules targeting structured RNAs. ACS Chemical Biology 11:1720−1728

doi: 10.1021/acschembio.6b00001
[142]

de Lajarte AA, Taillades Y, Aruda J, Bongrand P, Wightman FF, et al. 2026. Diverse database and machine learning model to narrow the generalization gap in RNA structure prediction. Science Advances 12:eadz4967

doi: 10.1126/sciadv.adz4967
[143]

Wang Y, Tang S-C. 2022. The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options. Cancer and Metastasis Reviews 41:975−990

doi: 10.1007/s10555-022-10066-y
[144]

Ravegnini E, Trabocchi A, Lenci E. 2025. Small-molecule RNA ligands: a patent review (2018–2024). Expert Opinion on Therapeutic Patents 35:675−693

doi: 10.1080/13543776.2025.2492759
[145]

Su X, Tong Y, Zanon PRA, Wang J, Tanaka T, et al. 2024. Unbiased RNA degrader identification uncovers an LC3B-recruiting chimera for COL15A1 mRNA degradation. Journal of the American Chemical Society 147:45157–45167

doi: 10.1021/jacs.5c14363
[146]

Su Y, Hammond MC. 2020. RNA-based fluorescent biosensors for live cell imaging of small molecules and RNAs. Current Opinion in Biotechnology 63:157−166

doi: 10.1016/j.copbio.2020.01.001
[147]

Seok H, Lee H, Jang E-S, Chi SW. 2018. Evaluation and control of miRNA-like off-target repression for RNA interference. Cellular and Molecular Life Sciences 75:797−814

doi: 10.1007/s00018-017-2656-0
[148]

Lee YT. 2024. Nexus between RNA conformational dynamics and functional versatility. Current Opinion in Structural Biology 89:102942

doi: 10.1016/j.sbi.2024.102942
[149]

Khaskia E, Benhamou RI. 2025. Leveraging RIBOTAC technology: fluorescent RNase L probes for live-cell imaging and function analysis. Heliyon 11:e41295

doi: 10.1016/j.heliyon.2024.e41295